Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22,330 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.
Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, Zhang H, Mehta-Shah N, Ding K, Liu Y, Li Z, Zhang L, Zheng M, Jin J, Yang H, Shuang Y, Yoon DH, Gao S, Li W, Zhai Z, Zou L, Xi Y, Koh Y, Li F, Prince M, Zhou H, Lin L, Liu H, Allen P, Roncolato F, Yang Z, Kim WS, Zhu J. Song Y, et al. Among authors: zhao w. Lancet Oncol. 2024 Jan;25(1):117-125. doi: 10.1016/S1470-2045(23)00589-2. Epub 2023 Dec 9. Lancet Oncol. 2024. PMID: 38092009 Clinical Trial.
Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study.
Cao XX, Jin J, Fu CC, Yi SH, Zhao WL, Sun ZM, Yang W, Li DJ, Cui GH, Hu JD, Liu T, Song YP, Xu B, Zhu ZM, Xu W, Zhang MZ, Tian YM, Zhang B, Zhao RB, Zhou DB. Cao XX, et al. Among authors: zhao wl, zhao rb. EClinicalMedicine. 2022 Oct 4;52:101682. doi: 10.1016/j.eclinm.2022.101682. eCollection 2022 Oct. EClinicalMedicine. 2022. PMID: 36313145 Free PMC article.
Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.
Wang Y, Li S, Pan Y, Li H, Parsons MW, Campbell BCV, Schwamm LH, Fisher M, Che F, Dai H, Li D, Li R, Wang J, Wang Y, Zhao X, Li Z, Zheng H, Xiong Y, Meng X; TRACE-2 Investigators. Wang Y, et al. Among authors: zhao x. Lancet. 2023 Feb 25;401(10377):645-654. doi: 10.1016/S0140-6736(22)02600-9. Epub 2023 Feb 9. Lancet. 2023. PMID: 36774935 Clinical Trial.
Synthesis of 64Cu-, 55Co-, and 68Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macrocycles.
Fonseca Cabrera GO, Ma X, Lin W, Zhang T, Zhao W, Pan L, Li X, Barnhart TE, Aluicio-Sarduy E, Deng H, Wu X, Rakesh KP, Li Z, Engle JW, Wu Z. Fonseca Cabrera GO, et al. Among authors: zhao w. J Nucl Med. 2024 Jun 13:jnumed.124.267469. doi: 10.2967/jnumed.124.267469. Online ahead of print. J Nucl Med. 2024. PMID: 38871388
Stroke-heart syndrome: current progress and future outlook.
Wang L, Ma L, Ren C, Zhao W, Ji X, Liu Z, Li S. Wang L, et al. Among authors: zhao w. J Neurol. 2024 Jun 13. doi: 10.1007/s00415-024-12480-4. Online ahead of print. J Neurol. 2024. PMID: 38869825 Review.
22,330 results
You have reached the last available page of results. Please see the User Guide for more information.